Becton, Dickinson and Company (LON:0R19)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 50.67B |
| Revenue (ttm) | 16.49B |
| Net Income (ttm) | 1.38B |
| Shares Out | n/a |
| EPS (ttm) | 4.75 |
| PE Ratio | 36.73 |
| Forward PE | n/a |
| Dividend | 3.09 (1.35%) |
| Ex-Dividend Date | Mar 10, 2025 |
| Volume | 1,286 |
| Average Volume | 1,564 |
| Open | 228.10 |
| Previous Close | 228.45 |
| Day's Range | 226.91 - 228.91 |
| 52-Week Range | 227.28 - 286.33 |
| Beta | 0.38 |
| RSI | 49.59 |
| Earnings Date | May 1, 2025 |
About LON:0R19
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system... [Read more]
Financial Performance
In 2024, LON:0R19's revenue was $20.18 billion, an increase of 4.16% compared to the previous year's $19.37 billion. Earnings were $1.71 billion, an increase of 19.73%.
Financial numbers in USD Financial StatementsNews
BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery
FRANKLIN LAKES, N.J. , March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Inves...
How Do Investors Really Feel About Becton Dickinson?
Becton Dickinson's (NYSE: BDX) short percent of float has fallen 21.09% since its last report. The company recently reported that it has 2.94 million shares sold short , which is 1.01% of all regular...
Becton, Dickinson and Company (BDX) Barclays 27th Annual Global Healthcare Conference Transcript
Becton, Dickinson and Company (NYSE:BDX) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:30 AM ETCompany ParticipantsTom Polen -...
Buy Two Ideal March 'Safer' Dividend Dogs Of 34 Barron's 2025 Pro-Picks
Barron's New-Year (NY) Roundtable (RT) selections published in three issues 1/13-27/2025, listed 34 dividend picks as the best of 2025. Analysts predict top picks like AdvanSix, Applied Materials, and...
The Dividend Aristocrats Ranked By Quality Scores: March 2025
S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index, expanding it to 69 companies. I rank Dividend Aristocrats by quality scores, presenting undervalued and overval...
Becton, Dickinson and Company (BDX) Citi's 2025 Unplugged Medtech and Life Sciences Access Day Transcript
My Best Dividend Aristocrats For March 2025
The ProShares S&P 500 Dividend Aristocrat ETF kicks off 2025 on a bright note with a gain of 2.81% in January. I present 3 strategies that can theoretically beat the dividend aristocrat index in the l...
BD to Present at Investor Healthcare Conferences
FRANKLIN LAKES, N.J. , Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following ...
Insider Sell: Bertram Scott Sells Shares of Becton Dickinson & Co (BDX)
Insider Sell: Bertram Scott Sells Shares of Becton Dickinson & Co (BDX)
Starboard pushes an open door at Becton Dickinson as company seeks to separate its biosciences unit
Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The company aims to do just that.
BD (BDX) Stock Drops Amid Market Volatility and Strong Financials
BD (BDX) Stock Drops Amid Market Volatility and Strong Financials
Becton Dickinson to Separate Biosciences and Diagnostic Solutions Business
Becton Dickinson to Separate Biosciences and Diagnostic Solutions Business
Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
On Wednesday, Becton, Dickinson and Company (NYSE: BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and ...
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
On Wednesday, Becton, Dickinson and Company BDX authorized to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-or...
Becton, Dickinson and Company 2025 Q1 - Results - Earnings Call Presentation
Becton, Dickinson confirms plans to separate life sciences business
Becton, Dickinson plans to separate its Biosciences and Diagnostic Solutions business, aiming to unlock value and accelerate innovation in MedTech. Read more here.
Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business
Becton Dickinson looks to separate life sciences unit
Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.
Becton, Dickinson Non-GAAP EPS of $3.43 beats by $0.44, revenue of $5.17B beats by $60M
Becton, Dickinson (BDX) reports Q1 fiscal 2025 results: Non-GAAP EPS beats by $0.44, revenue beats by $60M, shares down 2.94%.
Becton Dickinson & Co Surpasses Q1 Expectations with $3.43 EPS and $5.2 Billion Revenue
Becton Dickinson & Co Surpasses Q1 Expectations with $3.43 EPS and $5.2 Billion Revenue
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025 s...
BD Reports First Quarter Fiscal 2025 Financial Results
Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic GAAP and adjusted diluted EPS of $1.0...
Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit
Activist investor Starboard Value has taken a stake in Becton, Dickinson and Company (NYSE: BDX) and is pressing the $72 billion medical technology company to sell its life sciences division . The he...
Starboard Value pushes medical device maker Becton Dickinson to spin off unit
Activist investor takes stake in $72bn medical technology company in fund’s latest healthcare sector campaign